Hepatotoxic metabolite
- Marks a metabolite whose clinical significance IS its liver injury, not any receptor it binds
- 4-ene-valproate is formed by CYP-mediated desaturation of valproate and is implicated in valproate hepatotoxicity
- Its formation rises with enzyme-inducing co-medication, which is part of why polytherapy raises the risk
Drugs with this mechanism (1)
- 4-ene-VPA — Unsaturated valproate metabolite implicated in mitochondrial dysfunction and liver toxicity; not a separate therapeutic drug.
All mechanisms · Open the interactive console ↗